Nogapendekin Alfa Inbakicept

**Semantic type:** Pharmacologic Substance

**Definition:** A fusion protein soluble complex and interleukin-15 (IL-15) receptor agonist composed of nogapendekin alfa, a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and inbakicept, a fusion protein containing a dimeric IL-15 receptor alpha (IL-15Ra) sushi domain fused to human immunoglobulin G1 (IgG1) Fc (IL15Ra-Fc; IL-15RaSu-IgG1 Fc), with potential antineoplastic activity. Each fully assembled nogapendekin alfa inbakicept complex consists of a single inbakicept and two nogapendekin alfa components. Upon intravesicular administration, nogapendekin alfa inbakicept binds to the IL-2/IL-15 beta-common (bc) gamma chain (gc) receptor on natural killer (NK), CD8+ T lymphocytes and CD4+ T helper cells, which activates and increases the levels of NK cells, cytotoxic T-cells and memory T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.

**Synonyms:** - ALT 803 - ALT-803 - ALT803 - Anktiva - Fusion Protein Consisting of IL-15N72D and IL-15RASU/FC - IL-15N72D-IL-15RaSU/Fc - IL-15N72D/IL-15Ra-Fc - IL-15N72D/IL-15Ra-Fc - IL-15N72D:IL-15REC-SU/FC Soluble Complex I - IL-15N72D:IL-15RaSu/Fc Fusion Complex - Inbakicept Nogapendekin Alfa Fusion Complex - N 803 - N-803 - N803 - NOGAPENDEKIN ALFA INBAKICEPT - Nogapendekin Alfa Inbakicept-pmln - Nogapendekin alfa inbakicept - Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803